In Treatment of Bladder Cancer
IMMUCOTHEL®: biosyn immunocyanin in treatment of bladder cancer
Since 1985, biosyn has established a well-defined program for the development of therapeutic products in the area of bladder cancer in particular and cancer in general. IMMUCOTHEL®, containing the active ingredient, biosyn Keyhole Limpet Immunocyanin is the most advanced product investigated for the prevention of bladder carcinoma recurrences, after surgical removal of bladder carcinoma and in cases where other established therapies have failed.
Use of Hemocyanin in Bladder Cancer
The use of hemocyanin, KLH, in treatment of bladder cancer dates back to 1974. Olson et al. (J Urol 1974: 111, 173-176) reported a markedly reduced incidence of tumor recurrence in 10 patients with superficial bladder cancer who received 5 mg of subcutaneous KLH as a sensitizing dose followed by 200 µg intradermally, to assess cellular immune competence.
Since then, the utility of the immunotherapeutic approach in the treatment of bladder cancer has been well established with Bacillus Calmette-Guérin (BCG), which is currently the standard of care for carcinoma in situ (CIS) and Transitional Cell Carcinoma (TCC) of the urinary bladder.